Thirteen Abstracts Featuring Exelixis Compounds Accepted for Presentation at the 2009 AACR-NCI-EORTC International Conference

November 4, 2009

Includes Clinical Data for XL147, XL765 and XL139

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 4, 2009-- Exelixis, Inc. (Nasdaq: EXEL) announced today that thirteen abstracts related to the company's development candidates have been accepted for presentation at the 2009 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which is being held November 15-19 in Boston. Interim data from ongoing phase 1 clinical trials of XL147 and XL765 will be reported in four poster presentations. Exelixis is co-developing XL147 and XL765 in collaboration with sanofi-aventis. Clinical data for an ongoing phase 1 trial of XL139, which is being co-developed with Bristol-Myers Squibb, will also be reported. Other poster presentations will cover a variety of preclinical data and preclinical and clinical biomarker data for six compounds.

Clinical Data Presentations

- A phase 1 safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor, XL765 (SAR245409), in combination with erlotinib in patients (pts) with advanced solid tumors will be presented on Monday, November 16, 2009, during the 12:30 pm – 2:30 pm poster session (Abstract #A254)
- A first-in-human, phase 1 study of an oral hedgehog pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors will be presented on Monday, November 16, 2009, during the 12:30 pm – 2:30 pm poster session (Abstract #A55)
- A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients with advanced solid tumors will be presented on Tuesday, November 17, 2009, during the 12:30 pm – 2:30 pm poster session (Abstract #B247)
- A phase 1 safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with malignant glioma will be presented on Tuesday, November 17, 2009, during the 12:30 pm – 2:30 pm poster session (Abstract #B265)
- A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients with advanced solid tumors will be presented on Wednesday, November 18, 2009, during the 12:30 pm – 2:30 pm poster session (Abstract #C197)

Biomarker Data Presentations

- Pharmacodynamic and correlative biomarker analyses in clinical trials of XL184, an oral, potent inhibitor of MET, VEGFR2, and RET will be presented on Tuesday, November 17, 2009, during the 12:30 pm – 2:30 pm poster session (Abstract #B269)
- Characterization of the target profile of XL228, a multi-targeted protein kinase inhibitor in phase 1 clinical development will be presented on Wednesday, November 18, 2009, during the 12:30 pm – 2:30 pm poster session (Abstract #C192)

To access the clinical data posters mentioned in this press release, please visit www.exelixis.com. Please note that the clinical data posters will be available at time of presentation.

Preclinical Data Presentations

- Reduction of tumor invasiveness and metastasis and prolongation of survival of RIP-Tag2 mice after inhibition of VEGFR plus c-Met by XL184 will be presented on Monday, November 16, 2009, during the 12:30 pm – 2:30 pm poster session (Abstract #A13)
- Preclinical characterization of BMS-833923 (XL139), a hedgehog (HH) pathway inhibitor in early clinical development will be presented on Tuesday, November 17, 2009, during the 12:30 pm – 2:30 pm poster session (Abstract #B192)
- XL388: A novel, selective, orally bioavailable mTORC1 and mTORC2 inhibitor that demonstrates pharmacodynamic and antitumor activity in multiple human cancer xenograft models will be presented on Tuesday, November 17, 2009, during the 12:30 pm – 2:30 pm poster session (Abstract #B146)
- Discovery and characterization of selective PI3Kα and PI3Kα/mTOR-dual inhibitors for targeting PI3Kα-activated tumors will be presented on Wednesday, November 18, 2009, during the 12:30 pm – 2:30 pm poster session (Abstract #C59)

- Targeting tumor cell glycolysis: Discovery and characterization of small molecule inhibitors of IPFK2 (Inducible 6-Phosphofructo-2-Kinase) will be presented on Wednesday, November 18, 2009, during the 12:30 pm – 2:30 pm poster session (Abstract #C70)
- Assessment of Gli1 expression during skin regeneration in mouse models and normal healthy volunteers will be presented on Wednesday, November 18, 2009, during the 12:30 pm – 2:30 pm poster session (Abstract #C18)

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, sanofi-aventis, GlaxoSmithKline, Genentech, Boehringer Ingelheim, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's web site at www.exelixis.com.

Source: Exelixis, Inc.

Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President, Corporate Communications & Investor Relations
cbutler@exelixis.com